Cytokinetics reports strong start in 2026 with successful MYQORZO launch in US, China, and Europe.

Cytokinetics CEO Robert Blum shared that 2026 has begun well, highlighted by the successful launch of MYQORZO (formerly aficamten) following its approvals in the US, China, and Europe. The company is seeing positive momentum and encouraging early metrics in the treatment of obstructive hypertrophic cardiomyopathy (oHCM). Continued support and monitoring of the drug's market performance suggest a promising outlook for the rest of the year and into 2027.